Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $43 to $45.